Dr. Schuehsler serves as Chairman and CEO of TVM Capital Healthcare in Dubai and Singapore. TVM Capital Healthcare is a private equity investment platform created in 2009 focused on investing in and building transformational healthcare companies in the fast-growing emerging economies of the Middle East and Southeast Asia, including the expansion of Western companies into these regions. TVM Capital Healthcare closed its latest oversubscribed growth capital fund with a focus on Saudi Arabian healthcare transformation in the summer of 2024 at USD 254M and intends to mobilize total capital of more than USD 500M for about 10 portfolio companies in sub-sectors such as pharma, device, and diagnostics manufacturing, as well as single specialty clinics such as post-acute and chronic care, home health and disease management, reproductive medicine, oncology, cardiology and the rapidly growing field of digital health solutions.
In the Middle East, Dr. Schuehsler served as chairman or director of several healthcare growth companies since 2010, both in the field of specialized clinics as well as medical device manufacturing.
Since joining the original TVM Capital company (Techno Venture Management GmbH) in 1990 in Munich, Dr. Schuehsler has led the company through several transitions of ownership and strategy and has been the deal maker on more than 30 direct investments in life science and healthcare companies in Europe, the U.S., and the Middle East. During his tenure with TVM Capital from 1990-2012, he led the life science investment practice, raised more than US$1.2bn in committed capital, oversaw more than 100 investments in the health industry by teams out of Munich and Boston and had more than 50 IPOs and 30 M&A exit transactions in the portfolio. In this position as Managing Partner, he developed TVM Capital into the leading and largest life science investor in Germany in the 1990s, led the development of the firm into one of the leading pan- European and transatlantic investors. TVM Capital was for many years among the top ten investors in life sciences on the East Coast.
Starting in 2007, he spearheaded the expansion of the firm into the field of emerging market healthcare private equity which was domiciled in Dubai in 2009 and expanded to Singapore in late 2020. Both regional teams are currently fundraising for regional healthcare growth capital funds.
In terms of industry representation, from 2003 to 2007, Dr. Schuehsler served as Chairman of the Professional Standards Committee of the European Private Equity and Venture Capital Association (EVCA, now “Invest Europe”), where he led a team of up to 10 finance, audit and legal specialists as well as industry practitioners in the development or improvement of PE/VC industry guidance documents such as the Code of Conduct. In 2007, he was elected Chairman of EVCA. In 2014-2017, he also served on the Steering Committee of the MENA Private Equity Association.
On the technology commercialization and financing side, Dr. Schuehsler served as a member of the Technology Advisory Committee to chancellor Helmut Kohl in Germany, was a board member of Max-Planck Innovation GmbH in Munich for more than 10 years and was a member of the Selection Committee for the Technology Pioneers program and the Steering Committee of the Entrepreneurship and Successful Growth Research Program of the World Economic Forum for several years.